By Fineline Cube 
Merck & Co., Inc. (MSD; NYSE: MRK) announced the official commercial launch of Winrevair (sotatercept) in China, marking the introduction of the world’s first activin signaling inhibitor (ASI) for the treatment of pulmonary arterial hypertension (PAH). The therapy, approved by Chinese regulators in February 2026, targets adult patients with WHO functional class II-III PAH (WHO Group 1) and represents the first etiological treatment addressing the root cause of disease progression.
Regulatory Milestone & Indication Details
| Parameter | Specification |
|---|---|
| Drug Name | Winrevair (sotatercept) |
| Approval Date | February 2026 (China) |
| Indication | Adult patients with WHO FC II-III PAH (WHO Group 1) |
| Therapeutic Class | Activin Signaling Inhibitor (ASI) – first-in-class globally |
| Treatment Paradigm | Etiological therapy targeting disease root cause vs. symptomatic management |
Mechanism of Action & Clinical Innovation
- Molecular Profile: First fully human fusion protein specifically designed for PAH treatment
- Primary Target: Pulmonary vascular remodeling – the underlying pathological process in PAH
- Mechanism: Inhibits abnormal cell proliferation in pulmonary vasculature, reversing structural changes that drive disease progression
- Clinical Impact: Addresses heart failure component by improving right ventricular function through vascular normalization
- Therapeutic Gap: Fills critical unmet need for disease-modifying therapy in China’s estimated 25,000+ PAH patients
Market Context & Strategic Significance
- PAH Prevalence: China represents the second-largest PAH market globally with approximately 25,000-30,000 diagnosed patients
- Current Standard of Care: Limited to vasodilators and prostacyclin analogs that manage symptoms without halting disease progression
- Pricing & Access: Expected premium pricing (¥150,000-200,000 annually) with ongoing negotiations for national reimbursement listing
- Competitive Moat: Five-year data exclusivity protection with composition-of-matter patents extending to 2038
- Global Trajectory: China launch follows successful US/EU commercialization, positioning Merck to capture >40% of global ASI market by 2028
Pipeline Implications & Future Development
- Ongoing Studies: Phase III trials in WHO FC I and IV PAH patients expected to expand addressable population by 35%
- Combination Therapy: Investigational protocols combining Winrevair with existing PAH therapies show synergistic effects in early data
- Biomarker Development: Companion diagnostic for activin pathway activation may enable precision patient selection by Q4 2026
Forward‑Looking Statements
This brief contains forward-looking statements regarding product launches, regulatory approvals, and market expectations for Winrevair. Actual results may differ due to reimbursement decisions, competitive dynamics, clinical adoption rates, and evolving treatment guidelines.-Fineline Info & Tech